

42 (2)

J Rheumatol 2015;42;143-352  
<http://www.jrheum.org/content/42/2.citation>

1. Sign up for TOCs and other alerts  
<http://www.jrheum.org/alerts>
2. Information on Subscriptions  
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints  
[http://jrheum.com/reprints\\_permissions](http://jrheum.com/reprints_permissions)

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

# The Journal of Rheumatology

VOLUME 42: NO. 2

jrheum.org

FEBRUARY 2015

## Editorials

**Expanding Medical Marijuana Access in Canada: Considerations for the Rheumatologist**  
*M-A. Fitzcharles, S. Jamal* ..... 143

**Cannabis in the Treatment of Rheumatic Diseases: Suggestions for a Reasoned Approach** *H. Kalant* ..... 146

•  
**Lumpers and Splitters: Ongoing Issues in the Classification of Large Vessel Vasculitis**  
*P.C. Grayson* ..... 149

•  
**The Need for Preclinical Biomarkers in Systemic Autoimmune Rheumatic Diseases**  
*C. Landolt-Marticorena* ..... 152

•  
**Obstetric Antiphospholipid Syndrome: Has the Black Swan Swallowed a Red Herring?**  
*C.A. Clark, K.A. Spitzer, C.A. Laskin* ..... 155

**Obstetric Antiphospholipid Syndrome: Lobsters Only? Or Should We Also Look for Selected Red Herrings?**  
*P.L. Meroni, C.B. Chighizola, M. Gerosa, L. Trespidi, B. Acaia* ..... 158

## Articles

**Inhibition of PCSK6 May Play a Protective Role in the Development of RA**  
*F. Wang, L. Wang, H. Jiang, X. Chang, J. Pan* ..... 161

**Genetic Polymorphisms of *Foxp3* in Patients with RA**  
*A. Paradowska-Gorycka, M. Jurkowska, A. Felis-Giemza, et al* ..... 170

**Elevation of Serum Immunoglobulin Free Light Chains During the Preclinical Period of RA**  
*X. Deng, C.S. Crowson, S.V. Rajkumar, et al* ..... 181

**Cardiovascular Disease-related Hospital Admissions of Patients with Inflammatory Arthritis**  
*J. Ursum, M.M.J. Nielen, J.W.R. Twisk, et al* ..... 188

**Switching from IV to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety**  
*R. Reggia, F. Franceschini, A. Tincani, I. Cavazzana* ..... 193

**Evaluation of Left Atrial Function by Real-time 3-D Echocardiography in Patients with SLE**  
*K. Li, R. Wang, M. Dai, J. Lu, Y. Zou, X. Yang* ..... 196

**Elevated Serum Levels of Syndecan-1 Are Associated with Renal Involvement in Patients with SLE**  
*K-J. Kim, J-Y. Kim, I-W. Baek, W-U. Kim, C-S. Cho* ..... 202

**Prevalence and Significance of Persistently Positive Antiphospholipid Antibodies in Women with Preeclampsia**  
*C. Gonzalez-Echavarri, I. Villar, A. Ugarte, R. Larrieta, G. Ruiz-Irastorza* ..... 210

**The Circulating Cell-free microRNA Profile in SSc Is Distinct from Both Healthy Controls and SLE**  
*S.O. Steen, L.V. Iversen, A.L. Carlsen, et al* ..... 214

**Association Between Nailfold Capillaroscopy Findings and Pulmonary Function Tests in Patients with SSc**  
*I. Castellví, C.P. Simeón-Aznar, M. Sarmiento, et al* ..... 222

**Trabecular Bone Score in Female Patients with SSc: Comparison with RA and Influence of Glucocorticoid Exposure**  
*E. Koumakis, J. Avouac, R. Winzenrieth, et al* ..... 228

**IV Immunoglobulin May Be an Effective Therapy for Refractory, Active Diffuse Cutaneous SSc**  
*C.L. Poelman, L.K. Hummers, F.M. Wigley, C. Anderson, F. Boin, A.A. Shah* ..... 236

**Criterion-concurrent Validity of Spinal Mobility Tests in Ankylosing Spondylitis: A Systematic Review of the Literature**  
*M.P. Castro, S.M. Stebbings, S. Milosavljevic, M.D. Bussey* ..... 243

**Male Sexual Dysfunction and Ankylosing Spondylitis: A Systematic Review and Metaanalysis**  
*D. Fan, L. Liu, N. Ding, et al* ..... 252

**Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-TNF- $\alpha$  Drugs: An Italian Multicenter Study** *E. Lubrano, F.M. Perrotta, A. Marchesoni, et al* ..... 258

Contents continued on page xxii

<b>The Interleukin 33/ST2 Axis in Patients with Primary Sjögren Syndrome: Expression in Serum and Salivary Glands, and the Clinical Association</b> <i>S.M. Jung, J. Lee, S.Y. Baek, et al</i> . . . . .	264
<b>Echocardiographic Abnormalities in New-onset Polymyositis/dermatomyositis</b> <i>A. Péter, Á. Balogh, S. Szilágyi, et al</i> . . . . .	272
<b>Polymyositis/dermatomyositis and Malignancy Risk: A Metaanalysis Study</b> <i>Z. Yang, F. Lin, B. Qin, Y. Liang, R. Zhong</i> . . . . .	282
<b>PTPN22 R620W Polymorphism and ANCA Disease Risk in White Populations: A Metaanalysis</b> <i>Y. Cao, K. Liu, Z. Tian, et al</i> . . . . .	292
<b>Clinical Features and Radiological Findings in Large Vessel Vasculitis: Are Takayasu Arteritis and Giant Cell Arteritis 2 Different Diseases or a Single Entity?</b> <i>S. Furuta, C. Cousins, A. Chaudhry, D. Jayne</i> . . . . .	300
<b>Visual Manifestations in Giant Cell Arteritis: Trend over 5 Decades in a Population-based Cohort</b> <i>A.G. Singh, T.A. Kermani, C.S. Crowson, C.M. Weyand, E.L. Matteson, K.J. Warrington</i> . . . . .	309
<b>Is Statin Exposure Associated with Occurrence or Better Outcome in Giant Cell Arteritis? Results from a French Population-based Study</b> <i>G. Pugnet, L. Sailler, R. Bourrel, J-L. Montastruc, M. Lapeyre-Mestre</i> . . . . .	316
<b>Imbalance of Prevalence and Specialty Care for OA for First Nations People in Alberta, Canada</b> <i>C. Barnabe, B. Hemmelgarn, C.A. Jones, et al</i> . . . . .	323

<b>The SAPHO Syndrome: A Single-center Study of 41 Adult Patients</b> <i>F. Aljuhani, A. Tournadre, Z. Tatar, et al</i> . . . . .	329
<b>Cost of Illness and Determinants of Costs Among Patients with Gout</b> <i>B. Spaetgens, J.M.A. Wijnands, C. van Durme, S. van der Linden, A. Boonen</i> . . . . .	335

## Images in Rheumatology

<b>Dual-energy CT for the Evaluation of Calcinosis in SSc</b> <i>V. Hsu, M. Bramwit, N. Schlesinger</i> . . . . .	345
<b>A Vertebral Bite by an Aneurysm</b> <i>F. Verhoeven, D. Wendling</i> . . . . .	347
<b>Tumoral Calcinosis During the Course of Systemic Sclerosis</b> <i>A. Audemard, N.M. Silva, J. Boutemy, G. Maigné, B. Bienvenu</i> . . . . .	348

## Correspondence

<b>Chemerin and Cardiovascular Risk in RA after Interleukin 6 Receptor Blockade</b> <i>K. Makrilakis, K. Fragiadaki, P.P. Sfikakis, G.D. Kitas</i> . . .	349
<b>Reply</b> <i>P.H. Dessein, L. Tsang, G.R. Norton, A. Solomon</i> . .	349
<b>Comment on “Fibromyalgia and Physical Trauma: The Concepts We Invent”</b> <i>R. Mader, D. Buskila, M. Ehrenfeld</i> . . . . .	351
<b>Reply</b> <i>F. Wolfe</i> . . . . .	352
<b>Meetings in Rheumatology</b> . . . . .	X